Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03156114
Title This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boehringer Ingelheim
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

follicular lymphoma

Therapies

BI 754091

BI 754111

Age Groups: adult | senior
Covered Countries USA | ESP | CAN

Facility Status City State Zip Country Details
University of Miami Miami Florida 33136 United States Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
John Theurer Cancer Center Hackensack New Jersey 07601 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Tennessee Oncology, PLLC Nashville Tennessee 37203 United States Details
Froedtert and The Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
Cross Cancer Institute (University of Alberta) Edmonton Alberta T6G 1Z2 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 1Z9 Canada Details
BioVirtus Research Site Sp. z o.o. Józefów 05-410 Poland Details
Onco.Cent. - Instit. of Maria Sklodowskiej-Curie Warszawa 02-781 Poland Details
Hospital Universitari Dexeus Barcelona 08028 Spain Details
Hospital General Universitario Gregorio Marañón Madrid 28007 Spain Details
Hospital Universitario HM Sanchinarro Madrid 28050 Spain Details
Hospital Politècnic La Fe Valencia 46026 Spain Details
Sarah Cannon Research Institute London W1G 6AD United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field